Stockscreener 앱 받기
0.77%
전일 마감가:
$23.29
열려 있는:
$23.3
하루 거래량:
42.40M
Relative Volume:
1.02
시가총액:
$133.46B
수익:
$62.46B
순이익/손실:
$7.88B
주가수익비율:
17.00
EPS:
1.38
순현금흐름:
$11.22B
1주 성능:
-5.32%
1개월 성능:
-6.27%
6개월 성능:
-11.50%
1년 성능:
-23.43%
1일 변동 폭
$23.11
$23.52
1주일 범위
$23.11
$24.73
52주 변동 폭
$20.91
$31.32
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.48 | 135.37B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
764.00 | 682.35B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.28 | 402.82B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
196.61 | 334.40B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.30 | 225.78B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.39 | 205.28B | 63.62B | 16.41B | 17.04B | 6.49 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer’s TALZENNA Study: A New Hope for Prostate Cancer Treatment? - TipRanks
Pfizer’s Latest Clinical Study Update: Avelumab and Axitinib in Renal Cell Cancer - TipRanks
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win - Reuters
Pfizer’s New Study on PF-07934040: A Potential Game-Changer in Cancer Treatment? - TipRanks
Pfizer’s New Study on Abrocitinib: A Potential Breakthrough for Pediatric Eczema - TipRanks
Pfizer’s ABRYSVO Vaccine Study: A Boost for Investor Confidence? - TipRanks
Pfizer’s Phase 3 Study: Evaluating Co-administration of RSV and Shingles Vaccines - TipRanks
Moderna Fights Off Pfizer Challenge To Surviving mRNA IP - Law360
Moderna Wins UK Patent Battle Against Pfizer and BioNTech - BioSpace
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings - Yahoo Finance
Moderna's Key Patent Win Overshadowed By Gloomy Outlook - Benzinga
Pfizer/BioNTech lose appeal to reverse Moderna’s COVID vaccine patent win in U.K. - Seeking Alpha
How To Trade Pfizer Stock Ahead of Its Upcoming Earnings? - Trefis
Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says - MSN
Pfizer losses appeal in Moderna patent case - breakingthenews.net
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech - The Daily Reflector
Moderna Secures Major Patent Victory: UK Court Rules Pfizer Infringed COVID-19 Vaccine Technology - Stock Titan
Pfizer (PFE) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Trump Demands Pharma Companies Slash US Drug Prices in Letter - Bloomberg
Trump demands largest pharma companies slash US drug prices - Yahoo Finance
Purdue and Gleaners Food Bank to Open Pharmacy, Concerns Over Eli Lilly and Pfizer Relationship, IU Researchers get Top Awards, Ground Breaking for New Subsidized Housing - WFYI
Pfizer’s Promising Phase 2 Study on Advanced Breast Cancer Treatment - TipRanks
Pfizer’s Promising Phase 3 Study on NSCLC Treatment: A Market Game-Changer? - TipRanks
Pfizer’s New Hope: PF-08046031 Study in Advanced Melanoma and Solid Tumors - TipRanks
Pfizer’s MagnetisMM-32 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer’s Latest Study on HER2-positive Breast Cancer: A Real-World Perspective - TipRanks
Pfizer’s COVID-19 Vaccine Study: Key Insights and Market Impact - TipRanks
Pfizer and Astellas Advance Prostate Cancer Study with Promising Drug Combo - TipRanks
Pfizer’s Phase 3 Study on Elranatamab vs. Lenalidomide: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Pfizer and Genmab’s Tivdak Study: Assessing Ocular Safety in Cervical Cancer Treatment - TipRanks
Pfizer’s TALZENNA Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
Pfizer’s Sisunatovir Study: A Promising Step in RSV Treatment - TipRanks
Pfizer’s Elranatamab Study: A Real-World Insight into Multiple Myeloma Treatment - TipRanks
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Pfizer: Lack Of Enthusiasm Shouldn't Surprise You - Seeking Alpha
Where Will Pfizer (PFE) Be in 5 Years? - AOL.com
Bank of America Securities Maintains a Hold on Pfizer (PFE) - Insider Monkey
Pfizer Shares Plunge 2.02% Amid Vaccine Advances and Cancer Deal, Ranked 118th in $860M Trading Volume - AInvest
Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability - Insider Monkey
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Market Game-Changer? - TipRanks
Pfizer’s Phase 3 Study on Avelumab and Axitinib in Renal Cancer: A Market Game-Changer? - TipRanks
Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Pediatric Eczema - TipRanks
Pfizer’s Latest Clinical Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Middle East and Asia Pacific Biotechnology Market Is Booming So - openPR.com
Time to Go Short on Pfizer (PFE)? - Insider Monkey
Pfizer plans to continue work in Russia in years to come - The Pharma Letter
Australia Anti-Venom Market Analysis Report 2025-2033 - GlobeNewswire
Corneal Ulcer Treatment Market Driven by Innovation from Dr. Reddy’s to Pfizer, Set for Significant Growth - FMIBlog
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Pfizer Stock Is a Value Play Ahead of EarningsInvestors Can Short PFE Puts for Income - Yahoo Finance
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.09%
자본화:
|
볼륨(24시간):